Nurix enrolls first patient in Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed/refractory CLL/SLL
NRIX•Study design and patient target
The trial will test whether BTK degradation can deliver better clinical benefit than pirtobrutinib in patients who progressed on a covalent BTK inhibitor.
The global study targets about 620 patients, randomizing them to bexobrutideg 600 mg once daily or pirtobrutinib.
First patient enrolled in Phase 3 DAYBreak CLL-306
Nurix enrolled the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory CLL/SLL.
No new trial results were presented; the study is intended to generate future evidence to support global regulatory filings.
